MDMA - onset.to

Yesterday October 30, 2026

What Happened to DanceSafe? Founder Emanuel Sferios on Centralization, Corruption, Chapter Autonomy, and Harm Reduction Organizing

grassrootsharmreduction.org · Oct 30, 2026 · Emanuel Sferios

MDMA Article Community Ethics HarmReduction

October 27, 2026

Why pharmaceutical companies are investing billions in psychedelic drugs despite regulatory setbacks and unresolved safety questions

nature.com · Oct 27, 2026 · Lynne Peeples

Psilocybin MDMA Article Business +2

Why pharmaceutical companies continue investing billions in psychedelic drugs despite regulatory setbacks and unresolved safety questions

nature.com · Oct 27, 2026 · Lynne Peeples

Psilocybin MDMA Article Business +2

October 23, 2026

MDMA-assisted therapy for PTSD may gain FDA approval by early 2027, but a severe shortage of qualified therapists could limit access

nypost.com · Oct 23, 2026 · McKenzie Beard

MDMA Article Clinical Policy Therapy

FDA approval of psychedelics could drive an underground boom, requiring public health measures for risks and adverse events

ecstaticintegration.org · Oct 23, 2026 · Jules Evans

Psilocybin MDMA Article HarmReduction +2

October 22, 2026

MDA verursacht länger anhaltende Wirkungen und mehr Nebenwirkungen als MDMA in einer randomisierten Cross-over-Studie

psychedelia-stiftung.de · Oct 22, 2026

MDMA Article Clinical Research Safety DE

October 21, 2026

Jordan Kronick on Peaking, filming psychedelic healing, Ecstasy Rising, brain injury in sports, and drug policy

psychedelicstoday.com · Oct 21, 2026 · Psychedelics Today

Psilocybin MDMA Podcast Culture +2

October 14, 2026

The Psychedelic Practitioner Issue 7: Preparedness and the Systems Needed to Deliver Psychedelic Therapies

psychedelicalpha.com · Oct 14, 2026 · Alice Lineham and Josh Hardman

Psilocybin MDMA Article Clinical +2

October 13, 2026

Federal leaders call for national standards to safely integrate psychedelic-assisted therapies into U.S. health care

thehill.com · Oct 13, 2026 · Jack Bergman and Lou Correa

Psilocybin MDMA Article Clinical +2

October 2, 2026

Ohio's P.E.A.C.E. Program Trains Emergency Responders to Provide Safer, Supportive Care During Psychedelic Crises

psychedelicstoday.com · Oct 2, 2026 · Sara Gael, MA, LPC

Psilocybin MDMA Article Education +2

September 30, 2026

Eine einzelne MDMA-Dosis verhindert bei genetisch besonders gefährdeten Ratten einen traumabedingten Anstieg des Alkoholkonsums

psypost.org · Sep 30, 2026 · Eric W. Dolan

MDMA Article Clinical Research Safety DE

September 22, 2026

FDA hearing, VA psychedelic bill claims, and Alabama's marijuana rescheduling objection shape September 2026 policy briefing

psychedelicstoday.com · Sep 22, 2026 · Jack Gorsline

Psilocybin MDMA Article Industry +2

September 21, 2026

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

psychedelicalpha.com · Sep 21, 2026 · Josh Hardman

Ibogaine MDMA Podcast Industry +2

September 17, 2026

USA: Rund 9,5 Millionen Erwachsene haben 2025 Psychedelika mikrodosiert, laut national repräsentativer RAND-Befragung

psychedelia-stiftung.de · Sep 17, 2026

LSD Psilocybin Article Mainstream +3 DE

September 4, 2026

New Zealand authorizes two psychiatrists to prescribe MDMA for PTSD through an individual doctor pathway, without approving MDMA as a medicine

behavioralwire.com · Sep 4, 2026 · Behavioral Wire Staff

MDMA Article Clinical Policy Safety

New Zealand approves psychiatrist-prescribed MDMA-assisted therapy for adults with severe PTSD in controlled clinical settings

theguardian.com · Sep 4, 2026 · Agence France-Presse

MDMA Article Clinical Policy Therapy

August 31, 2026

Psychedelika und Psychoplastogene: Neue Ansätze für schnell wirksame Behandlungen von Depressionen und verwandten Erkrankungen

psychedelia-stiftung.de · Aug 31, 2026 · Markus Berger

Psilocybin MDMA Article Clinical +2 DE

August 30, 2026

Positive emotional states, not mystical experiences, may explain symptom relief in MDMA-assisted therapy for PTSD

psypost.org · Aug 30, 2026 · Eric W. Dolan

MDMA Article Clinical Research Therapy

August 22, 2026

Psychedelic raves emerge as modern rites of passage, with Israeli attendees reporting complex after-effects

psypost.org · Aug 22, 2026 · Bianca Setionago

LSD MDMA Article Culture +2

Ceremony length tracks drug duration across 11 traditions, linking psychedelic pharmacology with ritual structure and community response

ecstaticintegration.org · Aug 22, 2026 · Jules Evans

LSD Psilocybin Consciousness Culture +6

August 21, 2026

An embedded-brain view of psychedelic healing links serotonin 2A signaling, social context, and predictive processing in Johnson's theory of consciousness

themicrodose.substack.com · Aug 21, 2026 · jane c. hu

LSD Psilocybin Consciousness Philosophy +5

PharmAla’s patent, asset-retention strategy, and Canaccord partnership signal a push toward commercial leadership in psychedelic therapeutics

briefglance.com · Aug 21, 2026 · Christine Carter

MDMA Article Business Industry Research

August 20, 2026

Big pharma targets psychedelic medicine as patent strategies, drug development costs, and mental health demand reshape a fast-growing commercial market

marketplace.org · Aug 20, 2026

Psilocybin MDMA Business Industry +2

Meta-analysis finds MDMA raises oxytocin, peaking 150 to 200 minutes after administration and remaining slightly elevated for up to five hours

psypost.org · Aug 20, 2026 · Karina Petrova

MDMA Article Clinical Research Therapy

Australien erlaubt ab Juli 2023 den medizinischen Einsatz von Psilocybin und MDMA durch speziell zugelassene Psychiater bei therapieresistenten Störungen

psychedelia-stiftung.de · Aug 20, 2026 · Psychedelia Stiftung

Psilocybin MDMA Article Mainstream +2 DE